LINC02145

Across TCGA pan-cancer cohorts, LINC02145 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LINC02145 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LINC02145 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC02145 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, COAD, and DLBC are the cancer types where LINC02145 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.160	0.541	.003	18	view →
COAD	OS	Median	All	0.001	0.871	<.001	13	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LGG	DFS	Median	All	0.080	0.826	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.683	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LINC02145–OV (DFS)

Open the OV breakdown →